Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
House dust mite allergen tablets for prevention of childhood asthma
ISRCTN14917997Phase 2Recruiting
- Sponsor
- University of Southampton
- Start
- Nov 2025
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
01
Overview
Phase 2, randomised trial in asthma comparing Acarizax with Placebo (2 arms). Primary endpoints: Composite prevention endpoint at final year 3 visit, Recurrent wheeze component and 1 more. Started Nov 2025; status: recruiting.
02
Drugs
House dust mite allergen extract
03
Conditions
asthma
Beyond the preview
Go deeper on ISRCTN14917997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN14917997.